FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortuma…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
eLife

Non-visual light modulates behavioral memory and gene expression in C. elegans

Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, United States ...
Everyday Health on MSN

What Is the MS Prodrome?

Explore the concept of the MS prodrome, a period with subtle symptoms before multiple sclerosis onset. Learn about early ...
Medical Dialogues

Inflammation may be responsible for driving earliest stages of lung cancer, suggests research

By creating high-resolution cellular and molecular visual maps of lung cancer before and during development, researchers at ...
Thorax

Balloon dilatation for bronchoscope delivery: first-in-human trial of a novel technique for peripheral lung field access

Background Bronchoscopic limitations in reaching peripheral pulmonary lesions (PPLs) can compromise biopsy sensitivity, ...
IEEE

Multi-Pathway 3D CNN With Conditional Random Field for Automated Segmentation of Multiple Sclerosis Lesions in MRI

Abstract: Multiple Sclerosis (MS) is a chronic and autoimmune disease that causes lesions in the central nervous system. It is diagnosed based on accurate identification and segmentation of lesions in ...
IEEE

Visual–Semantic Fuzzy Interaction Network for Zero-Shot Learning

Abstract: Zero-shot learning (ZSL) aims to recognize unseen class image objects using manually defined semantic knowledge corresponding to both seen and unseen images. The key of ZSL lies in building ...
Technology Networks

Targeting Inflammation Could Halt Lung Cancer Before It Starts

Researchers used spatial transcriptomic mapping to reveal that inflammation drives the earliest stages of lung cancer. They ...
Emirates News Agency

Scientists identify main driver of early-stage lung cancer development

Researchers at the University of Texas MD Anderson Cancer Centre have discovered that inflammation may play a key role in ...

Ocugen outlines plans for three BLA filings in next three years amid global gene therapy expansion

Q3 2025 Management View CEO Shankar Musunuri highlighted the company's rapid progress on its modifier gene therapy platform, noting "in just over 3 years, we brought our lead candidate, OCU400, from ...